GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2018

Del

LYON, France, Nov. 05, 2018 (GLOBE NEWSWIRE) --

Article 223-16 of general regulation of French Autorité des Marchés Financiers
Lyon - France

Listing markets:
Euronext Paris from Euronext (Market segment B -  ISIN Code: FR0011471135- Symbol: ERYP) &
Nasdaq Global Select Market in the United-States (Symbol : ERYP)
Website : www.erytech.com

Date Total of shares composing the share capital Total of brut(1) voting rights   Total of net(2) voting rights
December 31, 2017 17 937 559(3) 19 545 443 19 542 943
January 1, 2018 17 940 035(3) 19 543 919(3) 19 541 419
February 28, 2018 17 940 035 19 546 219 19 543 719
March 31, 2018 17 940 035 19 546 221 19 543 721
April 30, 2018 17 940 035 19 554 221 19 551 721
May 31, 2018 17 940 035 19 543 991 19 541 491
June 30, 2018 17 940 035 19 525 991 19 523 491
July 31, 2018 17 940 035 19 525 991 19 523 491
August 31, 2018 17 940 035 19 525 991 19 523 491
September 30, 2018 17 940 035 19 525 741 19 523 241
October 31, 2018 17 940 035 19 525 741 19 523 241


(1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights.
(2) Without treasury shares
(3)  The number of shares and voting rights increased due to issuance of shares consequently to warrants exercises and or end of vesting periods of free shares which a Board of Director will take notice of in the future.

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results18.3.2019 21:45:00 CETPressemelding

On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on Tuesday, March 19 at 10:00 a.m. ET NEW YORK and CLEVELAND, March 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. Interested parties are invited to participate in the call by dialing 844-369-8770 (toll-free domestic) or 862-298-0840 (International) or via webcast at https://www.investornetwork.com/event/presentation/44847. “The diligent work conducted over the past nine months

Novavax Reports Fourth Quarter and Year-End 2018 Financial Results18.3.2019 21:05:00 CETPressemelding

Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018. “In 2018, we committed to focus on our two lead programs, ResVax™ and Nanoflu™, and reflecting on last year’s activities, I am proud to say we have achieved significant results for both,” said Stanley C. Erck, President and CEO of Novavax, Inc. “Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in a Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure. We are now prepared to make meaningful advances on these programs during 2019.” Fourth Quarter 2018 and Subsequent Opera

Mattson Technology Announces Hydrilis™, a Unique High-Productivity Vacuum Wafer Process Platform18.3.2019 17:00:00 CETPressemelding

– Up to 4 process chambers and 8 wafer processing stations – – Smallest footprint, highest throughput platform – – Enables any process chamber, any position configuration flexibility – FREMONT, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Mattson Technology, Inc., a leading supplier of advanced process equipment used to manufacture semiconductors, introduces Hydrilis™, the industry’s highest productivity density vacuum transfer platform featuring high throughput on the smallest footprint. The Hydrilis platform can be configured with up to 4 process chambers, or 8 processing stations, for parallel or sequential wafer processing. Any of the paradigmE® family plasma etch process chambers, Suprema® family plasma photoresist strip and hard-mask removal process chambers, Novyka™ family surface treatment process chambers and Novyka family selective chemical dry etch process chambers can all be integrated on the Hydrilis platform. “Throughput per unit area of fab space is one of the key criteria

Minerva Neurosciences to Host Webcast Event on Schizophrenia18.3.2019 13:30:00 CETPressemelding

Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a webcast, “Schizophrenia: Disease Landscape and Forecast,” on Thursday, March 21, 2019 beginning at 10:00 a.m. eastern time in Boston, MA. Minerva’s Executive Chairman and Chief Executive Officer, Remy Luthringer, Ph.D., will be joined by representatives from Decision Resources Group, a global information and technology services company providing proprietary data and solutions to the healthcare industry, and Dr. Gregory Strauss, an expert key opinion leader. Discussions will feature the following speakers

Infovista Enhances Ipanema SD-WAN with Nextgen Application Intelligence+ and Cloud-Native Orchestration18.3.2019 13:00:00 CETPressemelding

PARIS and ASHBURN, Va., March 18, 2019 (GLOBE NEWSWIRE) -- Infovista, the leader in modern network performance, today announced new cloud-native management and control with next-generation Application Intelligence+ for Ipanema SD-WAN, delivering unmatched application performance across any WAN. Tweet This: Infovista enhances Ipanema SD-WAN with nextgen Application Intelligence+ and cloud native orchestration: https://bit.ly/2ULcKLW #SmarterSDWAN The enterprise network has become the central nervous system of modern digital businesses, and SD-WAN is enabling this digital transformation. Infovista’s Ipanema SD-WAN with new cloud-native management and control of applications tightly combines session-based routing and dynamic path selection of the underlay network with an overlay of deep application visibility and dynamic control of the quality of experience for business-critical applications. Additionally, Ipanema automatically understands application delivery requirements and maintains a

Inspirata and Ohio State University Continue to Break Digital Pathology Barriers18.3.2019 12:30:00 CETPressemelding

Columbus, Ohio Columbus, Ohio, March 18, 2019 (GLOBE NEWSWIRE) -- Less than one year ago Inspirata announced that their digital pathology solution was used to make the first-ever primary digital diagnosis in the U.S., initiating a new era in cancer diagnostics. Today, cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced the company with the help of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC-James) has broken another barrier- Inspirata and the OSUCCC – James have scanned over one-million anatomic pathology slides into high resolution whole slide digital images. “This historic accomplishment has demonstrated that it is possible to create large repositories of diagnostic quality prospective and retrospective slides creating imaging data that will accelerate clinical and research efforts,” says Inspirata Scan Center Manager, Trina Shanks, MLT (ACSP), CPC. Inspirata will presen